Feature Channels: Pharmaceuticals

• share
• favorite_border

New research led by UCLA Health has found a drug that treats insomnia works to prevent the addictive effects of the morphine opioids in mice while still providing effective pain relief.

• share
• favorite_border

• share
• favorite_border

A new study suggests patients taking semaglutide — the active ingredient in Ozempic and Wegovy — may be at higher risk of developing an eye condition that can cause blindness.

• share
• favorite_border

Researchers at University of California San Diego show that a molecule which shuttles damaging inflammatory cells into cancer tumors also shuttles inflammatory cells into lung tissue infected with COVID-19 — and that the molecule can be suppressed with a repurposed cancer drug. The work represents a new approach to preventing irreversible organ damage in infectious diseases.

• share
• favorite_border

• share
• favorite_border

Scientists from Immanuel Kant Baltic Federal University found out that polymeric coating enables to improve the structure and properties of magnetoelectric composites, that are used in medicine for drug delivery and also in creation of implants and tissues. Thus, modification with polymer helps equal distribution of composite’s components, and also enhances its piezoelectric properties by 40%.

• share
• favorite_border

A pivotal study has demystified the genetic underpinnings of schaftoside, a vital compound in traditional Chinese medicine (TCM) with significant potential as a COVID-19 therapeutic. The research decodes the biosynthetic pathway and uncovers gene expansions within the Grona styracifolia genome, providing critical insights for optimizing the production of this promising medicinal agent.

• share
• favorite_border

Drugs that selectively kill senescent cells may benefit otherwise healthy older women but are not a "one-size-fits-all" remedy, Mayo Clinic researchers have found. Specifically, these drugs may only benefit people with a high number of senescent cells, according to findings publishing July 2 in Nature Medicine.

• share
• favorite_border

$5 million grant from the Agency for Healthcare Research and Quality will enhance long COVID care for underserved minority groups, community outreach, and research

• share
• favorite_border

The U.S. Supreme Court has blocked the Sackler family's bid for immunity from opioid-related lawsuits in a landmark decision. This ruling marks a pivotal moment in the ongoing opioid crisis, potentially reshaping how litigation against pharmaceutical companies is handled nationwide.

• share
• favorite_border

Moffitt Cancer Center researchers have developed a groundbreaking method for the scalable synthesis of withanolides.

• share
• favorite_border

• 97% of HER2+, early-stage patients treated with trastuzumab emtansine (T-DM1) were free of cancer recurrence five years after treatment • Prognostic test (HER2DX) shown helpful in identifying patients at greatest risk for recurrence

• share
• favorite_border

An expert from the Johns Hopkins Bloomberg School of Public Health is available for interviews to discuss the U.S. Supreme Court’s decision in Harrington v. Purdue Pharma.

• share
• favorite_border

NCCN shares new data on continued high prevalence for cancer drug shortages in the United States. In the latest survey, carboplatin and cisplatin shortages fell to 11% and 7% respectively, but 89% of centers surveyed continue to report shortages for at least one type of systemic therapy; 75% are experiencing two or more drug shortages.

• share
• favorite_border

Today, the Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC) released the results of a survey that ADLM conducted to determine how the Food and Drug Administration’s (FDA’s) final laboratory developed tests rule will impact patient access to essential tests. The survey found that, in spite of certain tests being exempt from the rule, it will still force many laboratories, particularly those in hospitals, to discontinue critical tests, including those needed to identify prescription and illegal drug use.

• share
• favorite_border

Medical products such as ointments or syringes reach their limits when it comes to delivering medication locally – and above all in a controlled manner over a longer period of time. Empa researchers are therefore developing polymer fibers that can deliver active ingredients precisely over the long term. These "liquid core fibers" contain drugs inside and can be processed into medical textiles.